Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Goff

Showing results (21-30 of 625) with videos related to

Pageof 63
Sort By:
Current Neuropharmacology|February 27, 2016
D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing PlasticityDonald C Goff
Evidence-Based Mental Health|October 27, 2009
Review: lamotrigine may be an effective treatment for clozapine resistant schizophreniaDonald C Goff
Harvard Review of Psychiatry|December 24, 2005
Pharmacologic implications of neurobiological models of schizophreniaDonald C Goff
The Harvard Mental Health Letter|March 26, 1999
What is the role of glutamate in schizophrenia?D C Goff
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 6, 2013
Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophreniaDonald C Goff
JAMA Psychiatry|February 21, 2019
Can Adjunctive Pharmacotherapy Reduce Hospitalization in Schizophrenia?: Insights From Administrative DatabasesDonald C Goff
Journal of Clinical Psychopharmacology|August 12, 2025
Reply to "Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia"Donald C Goff
Annals of Neurology|April 27, 2011
Lipids and stroke: looking for risk in all the wrong places?George Howard, David C Goff
Acta Psychiatrica Scandinavica|October 9, 2002
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinationsO Freudenreich, D C Goff
Annals of Epidemiology|September 17, 1998
A call for caution in the interpretation of the observed smaller relative importance of risk factors in the elderlyG Howard, D C Goff
Pageof 63

Showing results (21-30 of 625) with videos related to

Sort By:
Pageof 63
Current Neuropharmacology|February 27, 2016
D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing PlasticityDonald C Goff
Evidence-Based Mental Health|October 27, 2009
Review: lamotrigine may be an effective treatment for clozapine resistant schizophreniaDonald C Goff
Harvard Review of Psychiatry|December 24, 2005
Pharmacologic implications of neurobiological models of schizophreniaDonald C Goff
The Harvard Mental Health Letter|March 26, 1999
What is the role of glutamate in schizophrenia?D C Goff
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 6, 2013
Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophreniaDonald C Goff
JAMA Psychiatry|February 21, 2019
Can Adjunctive Pharmacotherapy Reduce Hospitalization in Schizophrenia?: Insights From Administrative DatabasesDonald C Goff
Journal of Clinical Psychopharmacology|August 12, 2025
Reply to "Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia"Donald C Goff
Annals of Neurology|April 27, 2011
Lipids and stroke: looking for risk in all the wrong places?George Howard, David C Goff
Acta Psychiatrica Scandinavica|October 9, 2002
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinationsO Freudenreich, D C Goff
Annals of Epidemiology|September 17, 1998
A call for caution in the interpretation of the observed smaller relative importance of risk factors in the elderlyG Howard, D C Goff
Pageof 63